三价CAR T细胞克服胶质母细胞瘤患者间抗原变异性
研究分析15例原发胶质母细胞瘤样本中HER2、IL13Rα2和EphA2的表面表达,并构建编码三种CAR分子的单载体三顺反子UCAR T细胞。UCAR T细胞均匀表达三种CAR,与肿瘤靶标形成免疫突触,细胞毒性和细胞因子释放优于单特异性和双特异性CAR T细胞。低剂量UCAR T细胞控制自体胶质母细胞瘤患者来源异种移植瘤并改善动物生存。
要点
- 同时靶向HER2、IL13Rα2和EphA2有覆盖多数肿瘤细胞的趋势,可克服患者间抗原变异性。
- UCAR T细胞均匀表达三种CAR分子,细胞毒性和细胞因子释放优于单特异性和双特异性CAR T细胞。
- 低剂量UCAR T细胞控制自体胶质母细胞瘤患者来源异种移植瘤并改善动物生存。
核心结论
- UCAR T细胞可克服胶质母细胞瘤的抗原异质性并带来改善的治疗结局。
研究设计与样本
- 分析15例原发胶质母细胞瘤样本中HER2、IL13Rα2和EphA2的表面表达,并构建由单一通用三顺反子转基因编码三种CAR分子的三价UCAR T细胞。
主要发现
- 共靶向HER2、IL13Rα2和EphA2有在本队列大多数肿瘤中捕获近100%肿瘤细胞的趋势,从而克服患者间变异性。
- 源自胶质母细胞瘤患者血液的UCAR T细胞均匀表达三种CAR分子,且各具不同抗原特异性。
- UCAR T细胞与肿瘤靶标形成更极化的微管组织中心免疫突触,且按每例患者肿瘤谱比较,细胞毒性和细胞因子释放优于最佳单特异性和双特异性CAR T细胞。
- 低剂量UCAR T细胞控制已建立的自体胶质母细胞瘤患者来源异种移植瘤并改善治疗动物生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is the most common primary malignant brain cancer, and is currently incurable. Chimeric antigen receptor (CAR) T cells have shown promise in GBM treatment. While we have shown that combinatorial targeting of 2 glioma antigens offsets antigen escape and enhances T-cell effector functions, the interpatient variability in surface antigen expression between patients hinders the clinical impact of targeting 2 antigen pairs. This study addresses targeting 3 antigens using a single CAR T-cell product for broader application. METHODS: We analyzed the surface expression of 3 targetable glioma antigens (human epidermal growth factor receptor 2 [HER2], interleukin-13 receptor subunit alpha-2 [IL13Rα2], and ephrin-A2 [EphA2]) in 15 primary GBM samples. Accordingly, we created a trivalent T-cell product armed with 3 CAR molecules specific for these validated targets encoded by a single universal (U) tricistronic transgene (UCAR T cells). RESULTS: Our data showed that co-targeting HER2, IL13Rα2, and EphA2 could overcome interpatient variability by a tendency to capture nearly 100% of tumor cells in most tumors tested in this cohort. UCAR T cells made from GBM patients' blood uniformly expressed all 3 CAR molecules with distinct antigen specificity. UCAR T cells mediated robust immune synapses with tumor targets forming more polarized microtubule organizing centers and exhibited improved cytotoxicity and cytokine release over best monospecific and bispecific CAR T cells per patient tumor profile. Lastly, low doses of UCAR T cells controlled established autologous GBM patient derived xenografts (PDXs) and improved survival of treated animals. CONCLUSION: UCAR T cells can overcome antigenic heterogeneity in GBM and lead to improved treatment outcomes.
引用
- Bielamowicz K, Fousek K, Byrd TT, et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018. PMID: 29016929. doi:10.1093/neuonc/nox182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。